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ABSTRACT
The study to monitor the adverse reactions related to cilostazol used in coronary arterial disease with congestive heart failure comorbidity. This 
case report describes monitored 63-year-old males with dyspnea that had recently begun using cilostazol after switched from aspirin caused by 
asthma related to aspirin. After 10 days monitored for adverse reactions of cilostazol used, revealed there was no adverse reaction to be related to 
cilostazol and the patient came home with improvement. Cilostazol did not show any adverse reactions in this report. However, more data and long-
term monitoring will needed. In addition, biologic variations may influence. Therefore, need to determine which population do not affect the harm of 
cilostazol.
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INTRODUCTION
Cardiovascular has been the leading cause of death in the world. Non-
ST elevated myocardial infarct is formed of coronary arterial disease 
that constitutes the most common cause of cardiovascular death. In 
the absence of contraindications, all patient with non-ST elevated 
should be treated in the emergency department with intranasal 
oxygen (if oxygen saturation is low), aspirin, clopidogrel, sublingual 
nitroglycerin, oral β-blockers, and an anticoagulant (unfractionated 
heparin, enoxaparin, fondaparinux, or bivalirudin) [1]. Moreover, in 
another clinical trials experiment showed the combination of aspirin, 
clopidogrel, and cilostazol reduced of thrombotic complication in 
the primary and secondary prevention of heart attacks. In addition, 
this triple antiplatelet reduced long-term cardiac and cerebral events 
after percutaneous coronary intervention (PCI) [2]. Cilostazol is a 
phospodiesterase III inhibitor (PDE III inhibitor) that has been approved 
by the FDA in 1999, the therapeutic target focus on cyclic adenosine 
monophosphate with the main effect is inhibited platelet aggregation 
(thrombosis), and dilation of the arteries contributes to supply blood to 
the legs [3-6]. Nevertheless, cilostazol contraindicated in patients with 
congestive heart failure and associated with increased mortality and 
adverse reactions such as cardiac arrhythmia, palpitation, tachycardia, 
and edema [3,7]. However, another PDE III inhibitors such as amrinone 
and milrinone are used in the treatment of heart failure [8]. Therefore, 
need closely monitored of cilostazole use in coronary arterial disease 
with heart failure comorbidity.
CASE REPORT
In July 2016, a 63-year-old male presented to the hospital with dyspnea. 
14 days before, he had experienced dyspnea and felt worse in 3 days 
ago. The patient had a history of well-controlled hypertension, post-
PCI, and he was on anticoagulant therapy.
On the physical examination, the arterial blood pressure was 
203/91, the heart rate was 109 mmHg, and the respiratory 
rate was 34/minute. Electrocardiography showed normal sinus 
rhythm, possible left atrial enlargement, inferior infarct, lateral 
ischemia. Echocardiography revealed an ejection fraction of 28%. 
Computed tomography scan showed acute infarct cerebral and 
did not appear any hemorrhage.
Laboratory study revealed an activated partial thromboplastin time 
23.2. Other test results were: hemoglobin - 10.4 g/dL; leukocyte 
- 7.100/mm3; thrombocyte - 287.000/mm3; hematocryte - 33%; 
troponin - I 0.04 ng/ml; creatinine - 10.9; sodium - 138 mmol/L; 
potassium - 6.1 mmol/L; chloride - 111 mmol/L, casual plasma 
glucose - 253 mg/dL; pH - 7.15.
The patient was diagnosed with non-ST elevated miocardiac infarct, 
hypertension, hypertension heart disease, congestive heart failure FC 
III-IV, chronic kidney disease, Type 2 diabetes mellitus, stroke, and the 
ejection fraction is 28%. At the time of his admission, his medications 
included farsorbid (2.5 mg/h), furosemide (5 mg/h), atorvastatin (once 
daily), lactulose (once daily), pantoprazole 40 mg intravenous (once 
daily), alprazolam (once daily), insulin 15 I.U. on dextrose 40%, calcium 
gluconas 4 g on dextrose 5%, losartan 50 mg (once daily 25 mg), 
calcium polystyrene sulfonate (TID), clopidogrel 75 mg (once daily if 
blood pressure <160 mmHg), aspirin 80 mg (once daily blood pressure 
<160 mmHg), and citcholine (BID 250 mg).
In the 2nd day, calcium gluconas 4 g on dextrose 5% was stopped. In the 
3rd day aspilet switched to cilostazole (BID 50 mg), losartan suspended 
and gave an additional drug of sodium bicarbonate (TID 500 mg). In 
the 4th day, gave an additional ketocid (TID). In the 5th day, calcium 
polystyrene sulfonate (TID) was insulin 15 I.U. on dextrose 40% was 
stopped and gave an addition of insulin garglin 12 I.U. (once daily). In 
the 6th day, losartan was used again and gave an addition combination of 
salbutamol nebulizer and budesonide nebulizer. On the 8th day was gave 
an additional of amlodipine 5 mg (once daily). In the 9th day, furosemide 
was switched to hydrochlorothiazide 12.5 mg (once daily) and was gave 
an addition of insulin aspart (TID 8 i.u.).
On the last physical examination, before the patient came home, the 
arterial blood pressure was 162/84 mmHg, the heart rate was 79 mmHg, 
and the respiratory rate was 17 times per minute. Electrocardiography 
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showed normal sinus rhytm, possible left atrial enlargement, and 
inferior infarct. The symptoms of dyspnea were disappeared.
Laboratory study revealed an activated partial thromboplastin time is 40.3. 
Other test results were: Creatinine - 9.6; sodium - 138 mmol/L; potassium 
- 3.6 mmol/L, and chloride - 108 mmol/L, casual plasma glucose - 126 mg/dL.
Until 12 days hospitalizations and 10 days consumed of cilostazol, there 
was not showed any adverse reactions. The patient came home with 
improvement.
DISCUSSION
In this present case reported switched of aspirin to cilostazol in the 
3rd day caused there were contraindication for asthma-related aspirin 
and 10 days consumed of cilostazol were not showed any adverse 
reactions that to be related of cilostazol. In addition, the dyspnea was 
disappeared, and there were not any symptoms felt of patient.
Although the FDA publishes warning about cilostazol contraindicated 
with patients heart failure of any severity and several drugs with this 
pharmacologic effect, have caused decreased survival compared to placebo 
in patients with Class III-IV heart failure [9]. However, the same group of 
cilostazol like amrinone and milrinone is used in the treatment of heart 
failure [8]. In a study, comparing the effect of cilostazol and milrinone 
caused similar increases in cyclic adenosine monophospate (cAMP) levels 
in human and rabbit platelets [10]. Inhibition of PDE III increase cAMP 
level cause dilation of smooth muscle, inhibition of platelet aggregation, 
contraction and increase heart rate, may this function improve the activity 
of the impair heart and blood circulation simultaneously. Therefore, need 
to determine which population do not affect the harm of cilostazol.
CONCLUSION
Cilostazol did not show any adverse reactions in this report. However, 
more data and long-term monitoring will needed. In addition, biologic 
variations may influence. Therefore, need to determine which 
population do not affect the harm of cilostazol.
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